בשל "הגנת זכויות יוצרים" מובא להלן קישור לתקציר המאמר. לקריאתו בטקסט מלא, אנא פנה/י לספרייה הרפואית הזמינה לך. 

Remimazolam is a new ultrashort acting benzodiazepine anesthetic which has predictable sedative duration and rapid recovery in gastrointestinal endoscopy.

Propofol is a commonly used intravenous anesthetic in clinical work which also has rapid action, short action time and rapid recovery.

To date, there have been relatively few articles comparing the two for general anesthesia induction. So, we conducted a randomized trial to evaluate whether remimazolam is superior to propofol during anesthesia induction in terms of efficacy and safety.

One hundred and eighty nine ASA I or II patients scheduled for elective surgery were divided into four groups: remimazolam 0.2 mg/kg (R1 group), 0.3 mg/kg (R2 group), 0.4 mg/kg (R3 group), and propofol group (P group).

All patients were anesthetized with single shots of experimental drugs during induction period.

Efficacy was measured by completing the induction of anesthesia without rescue sedation; and safety was defined as no severe adverse events.